Editas Medicine, Inc. (NASDAQ:EDIT) went up by 0.77% from its latest closing price when compared to the 1-year high value of $39.96 and move down -13.43%, while EDIT stocks collected 2.92% of gains with the last five trading sessions. Press Release reported on 08/24/20 that Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, Inc. (NASDAQ:EDIT) Worth an Investment?
Editas Medicine, Inc. (NASDAQ: EDIT) The 36 Months beta value for EDIT stocks is at 2.00, while 4 of the analysts out of 10 who provided ratings for Editas Medicine, Inc. stocks as a “buy” while 1 as overweight, 5 rated it as hold and 0 as sell. The average price we get from analysts is $43.00 which is $6.65 above current price. EDIT currently has a short float of 15.15% and public float of 60.92M with average trading volume of 1.06M shares.
EDIT Market Performance
EDIT stocks went up by 2.92% for the week, with the monthly jump of 19.99% and a quarterly performance of 24.84%, while its annual performance rate touched 41.88%. The simple moving average for the period of the last 20 days is 0.79% for EDIT stocks with the simple moving average of 26.88% for the last 200 days.
Analysts’ Opinion on Editas Medicine, Inc. (NASDAQ:EDIT)
Many brokerage firms have already submitted their reports for EDIT stocks, with SunTrust repeating the rating for EDIT shares by setting it to “Buy”. The predicted price for EDIT socks in the upcoming period according to SunTrust is $45 based on the research report published on June 18, 2020.
Wells Fargo, on the other hand, stated in their research note that they expect to see EDIT stock at the price of $28. The rating they have provided for EDIT stocks is “Equal Weight” according to the report published on February 21, 2020.
Evercore ISI gave “Outperform” rating to EDIT stocks, setting the target price at $28 in the report published on April 12, 2019.
EDIT Stocks 7.39% Far from 50 Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, Editas Medicine, Inc. was unable to take a rebound, for now settling with -11.84% of loss for the given period.
The stock volatility was left at 4.95%, however, within the period of a single month, the volatility rate increased by 3.54%, while the shares surge at the distance of +11.59% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +9.55% upper at the present time.
In the course of the last 5 trading sessions, EDIT went up by +2.92%, which changed the moving average for the period of 200 days to the total of +53.24% of gains for the stock in comparison to the 20-day moving average settled at $35.14. In addition, Editas Medicine, Inc. saw 18.98% in overturn over the period of a single year with a tendency to cut further gains.
EDIT Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Editas Medicine, Inc. (EDIT), starting from Collins Cynthia, who sold 1,976 shares at the price of $36.66 back on Aug 20. After this action, Rushing now owns 45,022 shares of Editas Medicine, Inc., valued at $72,440 with the latest closing price.
Albright Charles, the EVP/Chief Scientific Officer of Editas Medicine, Inc., sold 10,000 shares at the value of $35.29 during a trade that took place back on Aug 17, which means that Albright Charles is holding 28,135 shares at the value of $352,900 based on the most recent closing price.
EDIT Stock Fundamentals
The current profitability levels are settled at -686.39 for the present operating margin. The net margin for Editas Medicine, Inc. stands at -651.43. Total capital return value is set at -50.32, while invested capital returns managed to touch -48.26. Equity return holds the value -46.60%, with -26.40% for asset returns.
Based on Editas Medicine, Inc. (EDIT), the company’s capital structure generated 11.08 points for debt to equity in total, while total debt to capital is set at the value of 9.98.
The value for Enterprise to Sales is 51.24 with debt to enterprise value settled at 0.03. The receivables turnover for Editas Medicine, Inc. is 91.66 with the total asset turnover at the value of 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.74.